---
title: "60 DEGREES PHARMACEUTICALS, INC. 2026: Revenue $207.9K, EPS ($0.9) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295968027.md"
description: "60 DEGREES PHARMACEUTICALS reported Q2 2026 results with revenue of $207.9K, up 106% YoY, and a diluted loss per share of ($0.9), improving from ($5.01) in the prior year. The company achieved Nasdaq compliance via a reverse stock split, expanded partnerships including Runway Health and GoodRx, and ramped R&D for babesiosis trials."
datetime: "2026-08-14T19:41:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295968027.md)
  - [en](https://longbridge.com/en/news/295968027.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295968027.md)
generator: "portal-rs"
---

# 60 DEGREES PHARMACEUTICALS, INC. 2026: Revenue $207.9K, EPS ($0.9) — 10-Q Summary

60 DEGREES PHARMACEUTICALS, INC. reported results for the quarter ended 2026 with revenue of $207.9K, a net loss of ($2.4M), and diluted loss per share of ($0.9), compared with revenue of $100.93K, a net loss of ($1.84M) and diluted loss per share of ($5.01) in the prior-year quarter.

**Financial Highlights**

Metric

Current quarter

Prior year quarter

YoY change

Revenue¹

$207.9K

$100.93K

106%

Net income²

($2.4M)

($1.84M)

(30%)

Diluted EPS³

($0.9)

($5.01)

82%

*¹ Reported as “Product Revenues – net of Discounts and Rebates”. ² Reported as “Net Loss - attributed to common stockholders”. ³ Reported as “Diluted loss per Common Share (1)”.*

**Business Highlights**

-   Revenue growth: Product revenue rose 40% year-to-date to $370K, driven by increased shipments to third-party logistics providers despite flat pharmacy sell-through.
-   Channel shift: 3PL concentration increased to about 92% of U.S. net sales as Infuserve resumed purchasing via 3PL.
-   Access and partnerships: Expanded patient access through a Runway Health partnership and launched a GoodRx program in February 2026.
-   Corporate and operational milestones: Completed a 1-for-4 reverse stock split, regained Nasdaq compliance, and signed an FSU patent license for an Australian Chestnut extract.
-   Clinical and R&D activity: Ramped R&D with three active babesiosis trials and higher trial-related spending to support tafenoquine programs.

Original SEC Filing: 60 DEGREES PHARMACEUTICALS, INC. \[ SXTP \] - 10-Q - Aug. 14, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [SXTPW.US](https://longbridge.com/en/quote/SXTPW.US.md)
- [SXTP.US](https://longbridge.com/en/quote/SXTP.US.md)
- [GDRX.US](https://longbridge.com/en/quote/GDRX.US.md)

## Related News & Research

- [60 Degrees Pharmaceuticals seeks FDA national priority voucher for tafenoquine babesiosis sNDA](https://longbridge.com/en/news/298958475.md)
- [Rethinking Pharma Engagement in the AI Era](https://longbridge.com/en/news/298163938.md)
- [ISS: Sets new 2026-2028 targets: >5% organic growth, 5.5-6.0% margin, >60% cash conversion](https://longbridge.com/en/news/298867445.md)
- [Winthrop Wealth Named to the 2026 Inc. 5000](https://longbridge.com/en/news/298932734.md)
- [Intercont (Cayman) Limited Announces Effective Time of Share Consolidation/Reverse Share Splitto Regain NASDAQ Compliance | NCT Stock News](https://longbridge.com/en/news/298963607.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**